(NASDAQ: SLNO) Soleno Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.37%.
Soleno Therapeutics's revenue in 2025 is $0.On average, 5 Wall Street analysts forecast SLNO's revenue for 2025 to be $1,553,186,446, with the lowest SLNO revenue forecast at $318,249,600, and the highest SLNO revenue forecast at $2,320,378,925. On average, 5 Wall Street analysts forecast SLNO's revenue for 2026 to be $9,140,825,530, with the lowest SLNO revenue forecast at $1,605,005,185, and the highest SLNO revenue forecast at $11,597,308,894.
In 2027, SLNO is forecast to generate $20,760,191,780 in revenue, with the lowest revenue forecast at $2,872,500,708 and the highest revenue forecast at $36,575,775,302.